- Home
- ACVA vs JANX Comparison
ACVA vs JANX Comparison
Compare ACVA & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACVA | JANX |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.8B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ACVA | JANX |
|---|---|---|
| Price | $8.01 | $15.33 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $13.96 | ★ $62.00 |
| AVG Volume (30 Days) | ★ 3.2M | 2.5M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $735,475,000.00 | $10,000,000.00 |
| Revenue This Year | $21.22 | N/A |
| Revenue Next Year | $11.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23.40 | N/A |
| 52 Week Low | $4.95 | $15.16 |
| 52 Week High | $22.47 | $64.90 |
Technical Indicators
Market Signals| Indicator | ACVA | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 55.11 | 28.72 |
| Support Level | $8.00 | $16.00 |
| Resistance Level | $8.37 | $17.13 |
| Average True Range (ATR) | 0.33 | 1.55 |
| MACD | 0.15 | -1.31 |
| Stochastic Oscillator | 80.77 | 0.99 |
Price Performance
Historical ComparisonAbout ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.